{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:05:58Z","timestamp":1786964758166,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.clim.2011.01.006","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T04:04:15Z","timestamp":1295841855000},"page":"133-141","source":"Crossref","is-referenced-by-count":101,"title":["Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies"],"prefix":"10.1016","volume":"139","author":[{"given":"Melvin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Rojavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othmar","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2011.01.006_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2011.01.006_bb0010","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-007-9107-x","article-title":"A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma","volume":"27","author":"Berger","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1423-0410.2006.00764.x","article-title":"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia","volume":"90","author":"Bjorkander","year":"2006","journal-title":"Vox Sang."},{"key":"10.1016\/j.clim.2011.01.006_bb0025","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaci.2008.08.012","article-title":"Immunoglobulin therapy: methods of delivery","volume":"122","author":"Ballow","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0030","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0091-6749(98)70314-8","article-title":"Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product","volume":"101","author":"Stiehm","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"Berger","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/0003-4819-93-1-55","article-title":"Immunoglobulin replacement therapy by slow subcutaneous infusion","volume":"93","author":"Berger","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2011.01.006_bb0045","first-page":"120","article-title":"Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens","volume":"1","author":"Chouksey","year":"2005","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2249.1993.tb03380.x","article-title":"The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions","volume":"92","author":"Gardulf","year":"1993","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0091-6749(03)01781-0","article-title":"Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin","volume":"112","author":"Radinsky","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0070","series-title":"Hizentra immune globulin subcutaneous (human) [package insert]","year":"2010"},{"key":"10.1016\/j.clim.2011.01.006_bb0075","unstructured":"European Agency for the Evaluation of Medical Products Human Medicines Evaluation Unit. Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP\/BPWG\/283\/00), (2002)."},{"key":"10.1016\/j.clim.2011.01.006_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0085","series-title":"Vivaglobin immune globulin subcutaneous (human) [product information]","year":"2006"},{"key":"10.1016\/j.clim.2011.01.006_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0100","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaci.2009.07.051","article-title":"A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously","volume":"124","author":"Desai","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0105","first-page":"45","article-title":"Subcutaneous immunoglobulin replacement therapy","volume":"18","author":"Gustafson","year":"2002","journal-title":"Ellipse"},{"key":"10.1016\/j.clim.2011.01.006_bb0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF01541341","article-title":"Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency","volume":"14","author":"Waniewski","year":"1994","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med. J."},{"key":"10.1016\/j.clim.2011.01.006_bb0120","unstructured":"J.B. Hagan, M.B. Fasano, S. Spector, R. Wasserman, I. Melamed, M.A. Rojavin, O. Zenker, J. Orange, Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency, Blood, Manuscript in development."},{"key":"10.1016\/j.clim.2011.01.006_bb0125","unstructured":"S. Jolles, E. Bernatowska, J. De Gracia, M. Borte, V. Cristea, H.H. Peter, B.H. Belohradsky, V. Wahn, J. Neufang-Huber, O. Zenker, B. Grimbacher, Efficacy and safety of IgPro20 in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy, Clin Immunol, Manuscript in development."},{"key":"10.1016\/j.clim.2011.01.006_bb0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10875-010-9417-2","article-title":"Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels","volume":"30","author":"Thepot","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","article-title":"Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease","volume":"161","author":"Wasserman","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0140","unstructured":"Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey, (2003) Available at: http:\/\/www.primaryimmune.org\/publications\/surveys\/Treatment_Experiences_and_Preferences_(2003).pdf. Accessed January 2007, 2011."},{"key":"10.1016\/j.clim.2011.01.006_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.01.006_bb0150","unstructured":"M. Lucas, M. Lee, J. Lortan, E. Lopez-Granados, S. Misbah, H. Chapel, Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years, J Allergy Clin Immunol, 125 (2010) 1354\u20131360, e1354."},{"key":"10.1016\/j.clim.2011.01.006_bb0155","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2011.01.006_bb0160","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T03:57:09Z","timestamp":1543982229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661611000258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1521661611000258"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2011.01.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}